Background: The treatment of primary open-angle glaucoma (POAG) or ocular hypertension
(OHT) for intraocular pressure (IOP) reduction is recommended to proceed with the use of …

Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with other
intraocular pressure (IOP) lowering drugs for glaucoma and ocular hypertension (OHT), but …

Initial medical therapy for glaucoma typically consists exception. Although there are many
factors contributof topical medications that lower intraocular pressure ing to poor adherence …

Background The purpose of this study was to evaluate the safety and efficacy of a long-term,
twice-daily brinzolamide 1%/timolol 0.5% fixed combination ophthalmic suspension …

Glaucoma is a slowly progressive neuropathy with changes in the optic nerve, the retinal
neurofibrillar layer, and the field of vision. The aim of the paper is to present the significance …

The aim of this study was to evaluate changes in intraocular pressure (IOP), pupil size (PS),
blood pressure (BP), heart rate (HR), and ECG variables (Pms wave PmV, PR interval, QRS …

Purpose: To evaluate the short-term effect of fixed combination of brinzolamide 1% and
timolol 0.5%(FCBT) application on human central corneal thickness (CCT). Methods: This …

Purpose: The objective of this study was to assess preference for fixed-combination
brinzolamide 1%/timolol 0.5%(BTFC) versus fixed-combination dorzolamide 2%/timolol …

Results: Both groups had a statistically significant reduction in IOP from baseline (P=
0.0001). In the first group IOP reduction ranged from 7.0 to 12.0 mmHg (21.9–37.5%) while …

Purpose: We conducted a study to evaluate the effects of brinzolamide/timolol fixed
combination (BTFC) in normal-tension glaucoma (NTG) patients. Methods: We reviewed the …